Eagle Pharmaceuticals (NASDAQ:EGRX) declared that its board has initiated a share buyback program, which permits the company to buyback $100.00 million in shares on Wednesday, August 9th, EventVestor reports. This buyback authorization permits the specialty pharmaceutical company to repurchase up to 13.3% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s board believes its shares are undervalued.

A number of research analysts recently issued reports on the company. Piper Jaffray Companies set a $75.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday. BidaskClub downgraded Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, July 16th. Mizuho decreased their price target on Eagle Pharmaceuticals from $66.00 to $57.00 and set an “underperform” rating for the company in a research note on Thursday, May 25th. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, July 31st. Finally, ValuEngine upgraded Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 16th. Three equities research analysts have rated the stock with a sell rating and four have given a buy rating to the company. Eagle Pharmaceuticals has an average rating of “Hold” and a consensus price target of $75.40.

Shares of Eagle Pharmaceuticals (NASDAQ EGRX) traded up 3.5534% on Thursday, hitting $50.8965. The stock had a trading volume of 136,536 shares. The company has a market capitalization of $778.61 million, a price-to-earnings ratio of 7.9988 and a beta of 1.31. Eagle Pharmaceuticals has a 52 week low of $45.05 and a 52 week high of $97.15. The company has a 50-day moving average of $69.01 and a 200 day moving average of $76.30.

Eagle Pharmaceuticals (NASDAQ:EGRX) last released its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by $0.18. The business had revenue of $50.10 million during the quarter, compared to the consensus estimate of $52.52 million. Eagle Pharmaceuticals had a net margin of 44.48% and a return on equity of 79.25%. The business’s revenue was up 22.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.80 earnings per share. On average, equities research analysts predict that Eagle Pharmaceuticals will post $3.38 EPS for the current year.

In other Eagle Pharmaceuticals news, CFO Pete A. Meyers bought 350 shares of Eagle Pharmaceuticals stock in a transaction dated Monday, June 12th. The stock was bought at an average cost of $71.49 per share, with a total value of $25,021.50. Following the completion of the acquisition, the chief financial officer now directly owns 350 shares in the company, valued at approximately $25,021.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last ninety days, insiders bought 805 shares of company stock valued at $61,790. 19.50% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This story was posted by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.watchlistnews.com/eagle-pharmaceuticals-nasdaqegrx-announces-share-repurchase-program/1468703.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.